Advesya

Executive Summary

Advesya is a clinical-stage biotechnology company founded in 2020, headquartered in Paris, France, with Swiss operations. The company is pioneering novel therapies targeting IL-1RAP, a unique antigen overexpressed in multiple cancers and implicated in autoimmune diseases. Advesya is developing two complementary modalities: a CAR T-cell therapy and an antibody-drug conjugate (ADC). This dual-platform approach aims to address both hematologic and solid tumors, as well as autoimmune conditions, offering a differentiated strategy in the competitive immuno-oncology landscape. Currently in the pre-clinical stage, Advesya has not yet disclosed specific financial details or clinical trial initiations, but its focus on IL-1RAP represents an unexplored target with potential to treat diseases with high unmet medical need. The company's pre-clinical status and target selection position it for several near-term milestones. Advesya is expected to advance its lead programs toward Investigational New Drug (IND) filings and initial clinical trials within the next 12–18 months. However, as a private, early-stage biotech, it faces typical risks including financing requirements, regulatory hurdles, and competitive pressures from other IL-1RAP-targeted therapies. Conviction in Advesya is moderate given its early stage and lack of public data, but the novelty of the target and the dual-modality approach provide a differentiated investment thesis if initial data prove promising.

Upcoming Catalysts (preview)

• H2 2026IND filing for CAR-T program targeting IL-1RAP60% success
• Q3 2026Publication of preclinical efficacy data in solid tumor models70% success
• Q4 2026Series A financing round to support IND-enabling studies80% success